外照射放疗联合177Lu-PSMA配体治疗前列腺癌的进展
本综述系统检索PubMed与ClinicalTrials.gov等数据库,汇总外照射放疗(EBRT)联合177Lu标记PSMA配体治疗前列腺癌的临床前与临床研究及在研试验。一项临床前研究显示联合治疗较单药延长肿瘤生长延迟和生存,四项临床报告显示转移灶消退及生物有效剂量增加,十项在研前瞻性试验设计各异;结论认为该联合策略有望在不增加毒性下改善肿瘤控制,但最佳排程、剂量方案、剂量学作用及适应证仍需进一步研究。
要点
- EBRT联合177Lu-PSMA配体在临床前研究中显示较单药延长肿瘤生长延迟和生存。
- 已有临床报告显示转移灶消退及生物有效剂量增加。
- 十项在研试验覆盖不同患者人群、治疗排程与剂量分割方案。
核心结论
- EBRT联合177Lu-PSMA配体有望在不增加毒性的情况下改善不同阶段前列腺癌的肿瘤控制。
- 最佳治疗排程、剂量方案、剂量学作用及具体临床适应证仍需进一步研究以指导未来临床试验。
研究设计与样本
- 本综述在PubMed等在线研究数据库及ClinicalTrials.gov等试验数据库进行全面检索,收集EBRT联合177Lu标记PSMA配体治疗的临床前研究、临床研究和在研试验。
主要发现
- 一项已完成的临床前研究显示,与单药治疗相比,EBRT联合[177Lu]Lu-PSMA-617延长肿瘤生长延迟和生存,另一项研究显示叠加效应。
- 四项临床报告发表了该联合治疗的结果,包括显示转移灶肿瘤消退的系列报告和一项显示生物有效剂量增加的试点研究。
- 识别出十项正在进行的 prospective 临床试验,设计、患者人群(新发寡转移、寡复发和局部复发)、治疗排程([177Lu]Lu-PSMA配体新辅助、辅助、与EBRT同步)及放射剂量和分割方案各异。
局限性
- 最佳治疗排程、剂量方案、剂量学作用及具体临床适应证尚未确定,需进一步临床前和临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The combination of external-beam radiotherapy (EBRT) and 177Lu-labeled prostate-specific membrane antigen (PSMA) ligands may improve the outcome for specific prostate cancer indications. This review aims to introduce the concept of this combined treatment, provide an overview of preclinical and clinical studies (as well as ongoing trials), and address current challenges and future directions to investigate this emerging therapeutic approach. Methods: A comprehensive search was conducted in online research databases (including PubMed) and trial databases (including ClinicalTrials.gov) to gather all relevant preclinical and clinical studies and ongoing trials on the combination of EBRT and 177Lu-labeled PSMA ligands. Results: One completed preclinical study demonstrated increased tumor growth delay and survival with combined EBRT and [177Lu]Lu-PSMA-617, compared with monotherapies, and one an additive effect. Four clinical reports published results on this combination, including series showing tumor regression in metastatic lesions and a pilot study demonstrating an increased biologically effective dose. Ten ongoing prospective clinical trials with varying designs, patient populations (de novo oligometastatic, oligorecurrent, and locally recurrent), treatment schedules ([177Lu]Lu-PSMA ligands neoadjuvant, adjuvant, concurrent with EBRT), and radiation doses and fractionation schemes were identified. Conclusion: The combination of EBRT and [177Lu]Lu-PSMA ligands holds promise to improve tumor control without increasing toxicity across various stages of prostate cancer. However, optimal treatment scheduling, dosing regimens, the role of dosimetry, and specific clinical indications require further investigation through robust preclinical and clinical research to guide future clinical trials.
引用
- Teunissen FR, Oprea-Lager DE, Peters SMB, et al. Current Developments in Combining External-Beam Radiotherapy and 177Lu-Labeled PSMA Ligands for Prostate Cancer Treatment. J Nucl Med. 2025. PMID: 41044003. doi:10.2967/jnumed.125.270465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。